Company name: Ube Industries, Ltd.
Representative: Hiroaki Tamura
President and Representative Director
Shares listed on: First Section of Tokyo Stock Exchange,
Fukuoka Stock Exchange
Security code number: 4208
Contact: Yasuko Sakamoto
General Manager, IR/PR Department
Tel: +81-3-5419-6110

European Medicines Agency Issues Positive Opinion Recommending Approval of Prasugrel, Antiplatelet Agent

TOKYO, December 19, 2008 — Ube Industries, Ltd. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of prasugrel for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). Prasugrel is an investigational oral antiplatelet agent discovered by Ube Industries and Daiichi Sankyo Co., Ltd., and co-developed in the global market by Daiichi Sankyo and Eli Lilly and Company. The announcement by Ube Industries follows a separate joint press release issued yesterday by Daiichi Sankyo and Lilly.

The CHMP positive opinion is now referred for final action to the European Commission, which grants approval in the European Union (EU). The Commission usually makes a decision of an approval of a new drug candidate within two to three months of CHMP issuing its recommendation. Upon approval, Ube Industries will manufacture and supply the active pharmaceutical ingredient for the new oral antiplatelet agent, which is expected to be marketed throughout the EU under the proposed brand name Efient™.

Prasugrel works by inhibiting platelet activation and subsequent aggregation as a potential treatment, initially for patients with acute coronary syndromes who are undergoing PCI. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke. Lilly, on behalf of its alliance partner, Daiichi Sankyo, submitted a New Drug Application for prasugrel to the U.S. Food and Drug Agency (FDA) in December 2007, and a Marketing Authorization Application to the EMEA in February 2008.

Ube Industries earlier this year unveiled its Stage Up 2009 mid-term management plan, which identifies the Company's pharmaceuticals business as a developing business with future potential for growth and profitability. Accordingly, Ube Industries is engaging in pharmaceuticals R&D with the goal of discovering new and proprietary pharmaceutical agents that will benefit society. Ube Industries co-developed the Talion® antiallergic agent with Tanabe Seiyaku Co., Ltd. (presently Mitsubishi Tanabe Pharma Corporation), and co-developed the Calblock® antihypertensive agent with Sankyo Co., Ltd. (presently Daiichi Sankyo). Talion® and Calblock® were approved and marketed in Japan in 2000 and 2003 respectively, and it is anticipated that they will be followed by early approval of prasugrel in Europe.

- Efient™ is a trademark of Eli Lilly and Company.
- Talion® is a registered trademark of Mitsubishi Tanabe Pharma Corporation.
- Calblock® is a registered trademark of Daiichi Sankyo Co., Ltd.

For inquiries please contact:
Ube Industries, Ltd.
Investor Relations & Public Relations Dept.
Corporate Planning & Administration Office
Seavans North Building, 1-2-1 Shibaura, Minato-ku, Tokyo 105-8449
Tel: +81(3)5419-6110